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Background: Prostate cancer is a known cause of mortality in men worldwide although the risk factor varies
among different ethnic groups. Loss of the Y chromosome is a common chromosomal abnormality observed in the
human prostate cancer.
Results: We screened 51 standard sequence tagged sites (STSs) corresponding to a male-specific region of the Y
chromosome (MSY), sequenced the coding region of the SRY gene and assessed the status of the DYZ1 arrays in
the human prostate cancer cell lines DU145 and LNCaP. The MSY was found to be intact and coding region of SRY
showed no sequence variation in both the cell lines. However, DYZ1 arrays showed sequence and copy number
variations. DU145 and LNCaP cells were found to carry 742 and 1945 copies of the DYZ1, respectively per 3.3 pg of
genomic DNA. The DYZ1 copies detected in these cell lines are much below the average of that reported in
normal human males. Similarly, the number of “TTCCA” repeat and its derivatives within the DYZ1 arrays showed
variation compared to those of the normal males.
Conclusions: Clearly, the DYZ1 is maximally affected in both the cell lines. Work on additional cell lines and
biopsied samples would augment our understanding about the susceptibility of this region. Based on the present
work, we construe that copy number status of the DYZ1 may be exploited as a supplementary prognostic tool to
monitor the occurrence of prostate cancer using biopsied samples.
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The incidence of prostate cancer (PC) is increasing world-
wide though varies amongst different ethnic groups [1]. It
is a common malignancy affecting global population of
men and is a significant cause of morbidity and mortality.
The prevalence of this cancer is highest in the Western
countries and lowest in the Asian countries [2]. Despite its
high prevalence, very little is known about the molecular
mechanism of its tumorigenesis.
Reports are there suggesting the involvement of chromo-
somes 1, 5, 6, 7, 8, 10,12, 13, 17,18, 20, X and the Y
encompassing several genetically susceptible loci [3]
though their precise roles still remain unclear. The ad-
vanced stage of PC shows complex chromosomal changes* Correspondence: alisher@nii.ac.in
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reproduction in any medium, provided the oraccumulated during the tumour progression [3-7]. Loss of
the Y chromosome is a common chromosomal abnormal-
ity observed in the human PC [8] and this occurs only in
neoplastic, but not in stromal cells [9]. Loss of genetic ma-
terial may lead to the loss of putative tumour suppressor
genes, which will ultimately lead to cancer. This hypothesis
is supported by the fact that a normal human Y chromo-
some transferred to a Y chromosome lacking PC cell line
PC3, suppressed its tumorigenic property [8]. Genetic pre-
disposition of certain Y chromosomal haplogroups towards
PC strongly suggests a positive correlation [1,10,11]. How-
ever, study conducted on Korean population showed lack
of association between Y chromosomal haplogroups and
PC [12]. The involvement of several Y linked genes and
loci have been reported to be associated with the progres-
sion of PC [13,14]. The male sex determining gene SRY is
down regulated in PC and is a negative regulator of the an-
drogen receptor [15]. SRY does not express in any adulttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
















































































































Figure 1 Schematic representation of the human Y chromosome showing MSY region and positions of 51 STSs screened in DU145 and
LNCaP cells. Single copy genes, gene families and their corresponding STSs are shown on the vertical lines adjacent to the diagram of Y
chromosome. The vertical line on the right most side of the picture is showing presence of all the 51 STSs studied.
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Table 1 List of STSs analyzed to ascertain the genetic integrity of the Y-chromosome in the prostate cancer cell lines
DU145 and LNCaP




1 sY14 SRY exon 1 + +
2 sY1240 PCDH11Y intron 3 + +
3 sY276 AMELY exon 4/intron 4 + +
4 sY1238 TBL1Y exon 11 + +
5 sY637 PRKY 5’ upstream of gene + +
6 sY1319 PRKY 3’ UTR + +
7 sY1250 Proximal boundary of TSPY array + +
8 sY78 Alpha satellite (DYZ3) sequences in centromeric region * + +
9 sY1251 Boundary between centromere and Yq + +
10 sY1317 USP9Y exon 3 + +
11 sY1316 USP9Y exon 26 + +
12 sY1234 DDX3Y (DBY) exon 9 + +
13 sY1231 UTY exon 8 + +
14 sY1235 XKRY exon 1 * + +
15 sY1260 CDY2 exon 1 * + +
16 sY1237 HSFY exon 2 * + +
17 sY121 Immediately distal to palindrome P4 + +
18 sY1322 Between CYorf15A & CYorf15B + +
19 sY280 JARID1D (SMCY) exon 9/intron 9 + +
20 sY1233 EIF1AY exon 1 + +
21 sY1682 RPS4Y2 exon 1 + +
22 sY627 RBMY1 exon 12 * + +
23 sY1258 Boundary between unique sequence u1 & blue amplicon b1 in AZFc + +
24 sY1161 PRY intron 2 * + +
25 sY1197 Internal boundary of Palindrome P3 + +
26 sY1191 Unique sequence u3 in AZFc + +
27 sY1035 BPY2 intron 5 * + +
28 sY1318 DAZ exon 11 * + +
29 sY254 DAZ exon 3 * + +
30 sY1291 Red/gray boundary in AZFc + +
31 sY1125 Blue/gray boundary in AZFc * + +
32 sY1054 Blue/yellow boundary in AZFc * + +
33 sY1190 Yellow amplicon in AZFc * + +
34 sY1263 CDY1 exon 1/intron 1 * + +
35 sY1206 Yellow/green boundaries in AZFc * + +
36 sY1201 Distal boundary of gray amplicon in AZFc + +
37 sY1256 TSPY intron 5 * + +
38 sY1247 Boundary between PAR1 and MSY + +
39 sY1230 TMSB4Y exon 1/intron 1 + +
40 sY1166 In MSY between distal Yq heterochromatin & PAR2 + +
41 sY274 RPS4Y1 intron 4 + +
42 sY1220 VCY exon 2 * + +
43 sY90 KALP intron 1 + +
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Table 1 List of STSs analyzed to ascertain the genetic integrity of the Y-chromosome in the prostate cancer cell lines
DU145 and LNCaP (Continued)
44 sY210 STSP intron 5 + +
45 sY1254 TGIF2LY exon 1 + +
46 sY1239 NLGN4Y exon 1 + +
47 sY1273 Near boundary between MSY & PAR2 + +
48 sY238 ZFY intron 2 + +
49 sY1246 Proximal portion of distal Yq heterochromatin + +
50 sY142 Proximal to AZFc + +
51 sY160 Satellite-3 (DYZ1) sequences in distal Yq heterochromatin * + +
Multi-copy STSs are indicated by star (*) and plus (+) sign denotes the presence of a particular STS.
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expressed in DU145 [16], androgen untreated LNCaP cells
[13] and prostate adenocarcinoma cell lines. Thus, SRY
gene seems to play an important role for the development
and progression of PC.
The human Y chromosome is male specific, constitu-
tively haploid, passed on from father to son and largely es-
capes meiotic recombination. Approximately, 95% (60 Mb)
of the human Y chromosome represents non recombining
region of Y (NRY), also known as MSY. Similarly, 5%
(3 Mb) of the Y-chromosome is composed of pseudo-
autosomal region (PAR) necessary for the pairing with the
sex chromosomes. There are 1287 MSY specific STS
markers encompassing the human Y chromosome with an
average spacing of 14 Kb spanning over 1698 loci [17]. De-
letion mapping based on the STSs has advanced our un-
derstanding of the Y chromosome structure and functions.
Previous studies were mostly conducted on three commer-
cially available PC cell lines LNCaP, PC3 and DU145
using chromosome banding techniques [18], Fluores-
cence in situ hybridization (FISH) [19], Comparative
genomic hybridization (CGH) [20], and Spectral karyotyp-
ing (SKY) [21,22]. However, none of these techniques pro-
vided evidence towards the involvement of Y chromosome
linked genes and loci. In the present study, we studied
DU145 (originated from the metastatic site brain of a
69 years old Caucasian male) and LNCaP (originated from
the metastatic site left supraclavicular lymph node of a
50 years old Caucasian male) cell lines using 51 STSs spe-
cific to MSY. DU145 is Hypotriploid having both 61 and
62 chromosomes with highest rate of occurrence and
carries single Y per cell. The Y chromosome of DU145 car-
ries a translocated part of chromosome 20 [3]. LNCaP is
hypotetraploid having 84 chromosomes occurring in 22%
of the cells [23] and carries 2 Y chromosomes per cell [3].
Approximately, 20% of the human Y chromosome har-
bours DYZ1 satellite sequence [24]. DYZ1 was identified
as 3.4 Kb band generated on HaeIII digestion of the hu-
man male genomic DNA [25]. A normal human Y
chromosome contains approximately 4000–4300 copiesof the DYZ1 arrays [26]. Since DYZ1 copies do not par-
ticipate in recombination, it was deduced to have no
functional or evolutionary advantage [27]. However, this
is now reported to play a crucial role in chromatin fold-
ing and maintenance of the structural integrity of the Y
chromosome [26].
With this background, we studied status of several Y
linked genes and loci and assessed copy number vari-
ation of DYZ1 arrays using real time PCR in DU145 and
LNCaP cell lines. In addition, we sequenced the 3564 bp
unit of DYZ1 array and the coding region of SRY gene
from these cell lines.
Results
Status of the MSY region in DU145
The genomic DNA from DU145 and LNCaP was
screened for the presence or absence of 51 STSs specific
to MSY (Figure 1 and Table 1). These STSs in both the
cell lines were found to be intact.
HERV15 provirus sequence recombination
Human AZFa region contains HERV15 provirus A and
B sequences and homologous recombination between
these two regions accounts for most of the AZFa dele-
tions [28]. The AZFa regions of DU145 and LNCaP Y
chromosomes were found to remain intact showing the
presence of USP9Y and DBY genes (Figure 2).
Interstitial deletion mapping
There are known deletion patterns observed in different
clinical conditions e.g. AZFa, P5- proximal P1, P5- distal
P1, AZFc, gr/gr, b1/b2 and b2/b3 and TSPY-TSPY dele-
tion [29-36]. We have screened STSs encompassing
these regions which were found to remain intact in
DU145 of LNCaP cells (Figure 3).
DAZ SNV analysis
The normal Y chromosome harbours four copies of DAZ
gene [37]. The SNV analysis of DAZ was conducted using
appropriate enzymes [38] to digest PCR products (Table 2).






































Positive Control    +        +              +      +               +                            +         +         +     +      +        +                 +
DU145     +        +              +      +               +                            +         +         +     +      +        +                 +
LNCaP    +        +              +      +              +                            +         +         +     +      +         +                +
Figure 2 Deletion breakpoints mapping of AZFa region in DU145 and LNCaP based on STS analysis. Schematic diagram showing positions
of proviruses A and B. Light and dark grey blocks are the regions of identical sequences in the proviruses A and B involved in recombination. 12
STSs specific to proviruses A and B are shown along with the corresponding positive controls.
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ence of both alleles A and B for the SNVs (DAZ-
SNV_I, DAZ-SNV_II, DAZ-SNV_III, DAZ-SNV_IV,
DAZ-SNV_V, DAZ-SNV_VII, GOLY-SNV_1, TTTY4)
screened. For DAZ-SNV_VI and BPY2, DU145 showed
both the alleles A and B while LNCaP had only allele
A (Table 2).
SRY gene sequence
We amplified 824 bp fragment of the SRY exon having
615 bp long coding fragment (Table 3B), cloned and se-
quenced. The sequences of the SRY gene in both DU145
and LNCaP were found to be intact (see Additional file 1).
Status of the DYZ1 array
For ascertaining structural status of the DYZ1 array,
6 sets of primers were designed (Table 3A) to amplify 19
fragments (Table 4) from a single 3.56 kb array of DYZ1
(Figure 4). The analysis of all the 19 combinations showed
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Figure 3 STS map showing common interstitial deletions of the huma
Plus sign and blank spaces denote the presence and absence of a particula
studies are given on the right [see references 29-36]. Last row shows the reCopy number calculation of DYZ1 using real time PCR
We calculated DYZ1 copy number in DU145 and
LNCaP by Real Time PCR using SYBR green chemis-
try employing absolute quantification method and a
standard curve of cloned DYZ1 plasmid using ten-fold
dilutions starting with 20 crore (2x108) copies. The
amplification plot, dissociation curve and standard
curve are given in Figure 5A, B, and C, respectively.
Figure 5D represents the number of DYZ1 copies.
DU145 contains 742 copies, while LNCaP contains
1945 copies per 3.3 pg of genomic DNA.
3564 bp array sequence of DYZ1
Four PCR amplified fragments (Figure 4, dark bar) were
cloned and sequenced. Sequencing results showed inser-
tion, deletion and several point mutations. Compared to
normal sequences of the DYZ1, the number of highly
abundant “TTCCA” repeats [25] and its derivatives per
3564 bp (HaeIII fragment) were found to be different
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PS
n Y chromosome based on different studies conducted earlier.
r STS, respectively. The corresponding references related to these
sults of the present study denoted as PS.
Table 2 Details of the SNVs studied for DAZ, GOLY, BPY2 and TTTY4 genes








Fragments Alleles Present in
copies
DU145 LNCaP
DAZ-SNV_I SA 770 CACAGGCACTCAGTAACTATCTC G73167 709 Fsp1 TGC/GCA 709 A 1,2,3
4
A&B A&B
398 + 311 BSA771CAGTGTTTCACCCACCACTTCTGGGT
DAZ-SNV_II SA 446 GACATCCACGTCATTAACAAACG G73166 182 Mbo1 /GATC 182 A 1
2,3,4
A&B A&B
122 + 60 BSA 447 GGAAGCTGCTTTGGTAGATAC
DAZ-SNV_III
(sY586)
SA 772 GTGTGGCACATATGCCTATAAA G63907 301 Taq1 T/CGA 301 A 2
1,3,4
A&B A&B
184 + 117 BSA 773 TTGGTACATCCAGATGCAGAT
DAZ
gene
DAZ-SNV_IV SA 774 CTTCCTCATCTTTCTTGACTT G73168 630 AluI AG/CT 630 A 2
1,3,4
A&B A&B
398 + 262 BSA 775 TTATTTATTCCTCAAAAAGGTG
DAZ-SNV_V
(sY587)
SA 444 TGGTTAATAAAGGGAAGGTGTTTT G63908 244 DraI TTT/AAA 195 + 49 A 3,4
1,2
A&B A&B
122 + 73 +
49
BSA 445 TCTCCAGGACAGGAAAATCC
DAZ-SNV_VI SA 776 GGGCCTAGTCTCTAGATCATT G73169 431 AflIII A/CRYGT 431 A 1,2,3
4
A&B A
248 + 183 BSA 777 GCTAGAACCAAATATTCTGGAT
DAZ-SNV_VII
(sY581)
SA 442 CACTGCCCTAATCCTAGCACA G63906 252 Sau3AI /GATC 189 + 63 A 1,4
2,3
A&B A&B
130 + 63 +
59
BSA 443 TCTTCTGGACATCCACGTCA
GOLY1 GOLY-SNV_1 SA768 TTGGCCTGTTGCTTCTAGGGTT BV012733 531 HhaI GCG/C 531 A 1 Copy A&B A&B
SA769 ACAGGGAGGGTGCTGTCACA 289 + 282 B 1 Copy
BPY2 BPY2 SA766 AAGCCCATTGCTGAGATACTG BV012732 470 EcoRV GAT/ATC 470 A 2 Copy A&B A
SA767 TTGTGATTCTGACCCAACGA 289 + 181 B 1 Copy
TTTY4 TTTY4 SA764 TGCAGACAGCACTGTGGCTT BV012731 541 HaeIII GG/CC 541 A 1 Copy A&B A&B



















Table 3 List of primers used for PCR amplification of DYZ1 array (A) and SRY gene (B)
(A)
Serial No. Primer ID Primer Sequence Length (bp) Location (DYZ1 array) Orientation
1 SAS 1 CCATTCGAGACCGTAGCAAT 20 35-16 (5’ upstream to HaeIII site) 5’-3’
2 SAS 2 TTTCCTTTCGCTTGCATTCCAT 22 63-84 5’-3’
3 SAS 3 ATTTGATGCCATCCCATGAC 20 763-782 5’-3’
4 SAS 4 TTTTGAGTCCGTTCCATAACAC 22 1380-1401 5’-3’
5 SAS 5 TCCTTTGCCTTCCATTCG 18 1668-1685 5’-3’
6 SAS 6 TGCAGTCTTTTCCCTTCGAG 20 2564-2583 5’-3’
7 SAS 7 ATTGGATGGGATTGGAATGA 20 861-880 3’-5’
8 SAS 8 TGGATGGACTGCAATAGAAAG 22 1600-1621 3’-5’
9 SAS 9 TCGAATGGAAGGCAAAGG 18 1669-1686 3’-5’
10 SAS 10 CGACTGGTACGGACTCCAAT 20 2637-2656 3’-5’
11 SAS 11 GACTGGAAAGGCTGGGTGTCGA 22 3419-3440 3’-5’
12 SAS 12 TGGACAGCCTGGAATAAAGTG 21 3586-3606 3’-5’
(B)
1 SA 531 GAATCTGGTAGAAGTGAGTTTTGGA 25 61-85 5’-3’
2 SA 532 GCCTTTATTAGCCAGAGAAAAGAAA 25 860-884 3’-5’
Table 4 List of DYZ1 primer combinations used for end










1 SAS (1&7) 915 64°C-1.0’, 72°C −1.0’
2 SAS (1&8) 1656 65°C −1.0’, 72°C −2.0’
3 SAS (1&9) 1721 61°C −1.0’, 72°C −2.0’
4 SAS (2&7) 818 61°C −1.0’, 72°C −1.0’
5 SAS (2&8) 1559 60-°C 1.0’, 72°C −1.5’
6 SAS (3&7) 118 55-°C 1.0’, 72°C −1.0’
7 SAS (3&8) 859 65°C −1.0’, 72°C −1.0’
8 SAS (3&9) 924 61°C −1.0’, 72°C −1.0’
9 SAS (3&10) 1894 64-°C 1.0’, 72°C −2.0’
10 SAS (4&8) 242 61°C −1.0’, 72°C −1.0’
11 SAS (4&9) 307 55°C −1.0’, 72°C −1.0’
12 SAS (4&10) 1277 61°C −1.0’, 72°C −1.5’
13 SAS (4&11) 2061 62°C −1.0’, 72°C −2.5’
14 SAS (4&12) 2192 61°C −1.0’, 72°C −2.5’
15 SAS (5&10) 989 61°C −1.0’, 72°C −1.0’
16 SAS (5&12) 1904 61°C −1.0’, 72°C −2.0’
17 SAS (6&10) 93 61°C −1.0’, 72°C −1.0’
18 SAS (6&11) 877 61°C −1.0’, 72°C −1.0’
19 SAS (6&12) 1008 64°C −1.0’, 72°C −1.0’
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http://www.biomedcentral.com/1471-2164/14/323Additional file 2). The DYZ1 sequences from both DU145
and LNCaP cells were aligned with the reference sequence
from NCBI database (Accession no. AC068123.5, Gene
ID- 100499443) using ClustalW software (see Additional
file 3). Between DU145 and the reference sequence; 23
point mutations, between DU145 and LNCaP; 11 point
mutations and between LNCaP and the reference se-
quence; 27 point mutations were detected. Compared to
the reference DYZ1 sequence, DU145 showed Insertion of
16 bp in between the position of 1654- and 1655 bp, dele-
tions of 1 bp at position 792 bp and 15 bp between 2606–
2622 position, respectively. LNCaP showed insertion of
15 bp between 1654- 1655 bp position and deletion of
114 bp between 2541–2657 bp. The regions showing
major deletions are given in Figure 6 (For complete de-
tails, please see Additional file 3). A comparison of LNCaP
with DU145 showed a net deletion of 99 bp in LNCaP.
Upon virtual restriction mapping of 3.56 Kb unit of DYZ1
using Restriction Mapper version 3 software, loss and gain
of several restriction sites were detected (Table 6). Com-
pared to the reference sequence, a total of 6 restriction en-
zyme sites (BsaBI, NlaIV, BamHI, EcoRII, XhoII and
CspCI) were lost and Eco57I site was gained in DU145.
Similarly, a total 8 restriction enzyme sites (BsaBI, NlaIV,
BamHI, EcoRII, XhoII, CspCI, MaeII and MaeIII) were
lost and Eco57I site was gained in LNCaP. Thus, one
Eco57I site was gained in both the cell lines. Differences in
the restriction site frequency were compared amongst
DU145, LNCaP and the reference sequence (Table 6). The









































































Figure 4 Diagrammatic illustration showing end point PCR for the amplification of different sub-fractions of the DYZ1 array in DU145
and LNCaP cells. A single array of DYZ1 is shown on top. Forward and reverse primers are shown above and below the bars. Similarly, amplification
products and their corresponding sizes are shown below. The fragments highlighted (dark bar) were used for subsequent cloning and sequencing analysis.
Figure 5 DYZ1 sequence showing insertion and deletion. Partial aligned DYZ1 sequence from DU145 and LNCaP showing insertion and deletion
compared to that of the reference sequence AC068123.5.
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Table 5 Occurrence of “TTCCA” repeats and its
derivatives with single or multiple base alterations per






Number of TTCCA repeat units
and its derivatives per 3564 bpHaeIII
unit of DYZ1 array
AC068123.5 DU145 LNCaP
1 Actual Size (bp) 3564 3564 3465
2 TTCCA 229 235 228
3 1 bp derivatives 292 289 282
4 ATCCA 11 9 9
5 TACCA 3 3 2
6 TTACA 14 13 15
7 TTCAA 21 22 22
8 TTTCA 19 19 19
9 TTCTA 25 25 25
10 TTCCT 32 33 33
11 GTCCA 27 31 28
12 TGCCA 9 10 10
13 TTGCA 25 22 22
14 TTCGA 60 60 57
15 TTCCG 18 17 16
16 CTCCA 14 14 14
17 TCCCA 6 4 4
18 TTCCC 8 7 6
19 2 bp derivatives 142 142 139
20 3 bp derivatives 37 33 30
21 4 bp derivatives 9 9 10
22 5 bp derivatives 1 1 1
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The prostate cells DU145 might have encountered many
changes including translocation of the part of 20th
chromosome to the Y chromosome. The DU145 Y
chromosome was found to harbour only 742 copies of
DYZ1 which is far less than that in a normal Y chromo-
some. The DYZ1 constitutes approximately 20% of the
normal human Y chromosome needed for the mainten-
ance of its structural and functional integrities. A de-
crease in the number of arrays seems to threaten the
survival of Y chromosome in DU145 cell. To ascertain
the presence or the absence of Y chromosome in DU145
cells, we conducted FISH experiment using a labelled
DYZ1 probe. Approximately, 400 nuclei and metaphases
were screened. To rule out the possibility of experimen-
tal error, as a positive control, the metaphases from the
normal human male were hybridized with DYZ1 probe.
Several nuclei and metaphases in DU145 were found to
be devoid of DYZ1 fluorescence signals. This way,approximately, 48% of DU145 cells were found to have
no Y chromosome (Figure 7).
Discussion
DU145 and LNCaP cells originated from prostate tu-
mours. Despite involvement of several chromosomes in
the etiology of PC, our focus remained on the Y chromo-
some of the two cell lines to assess several Y linked
genes and DYZ1 regions. Sequences of the SRY gene
were found to be normal in both the cells. Previous
studies conducted on PC cell lines employed conven-
tional G-banding, FISH, CGH and SKY approaches.
However, these techniques owing to innate limitations, do
not detect microdeletions. Despite 51 STSs encompassing
AZFa, AZFb and AZFc screened in this study, no
microdeletions were detected suggesting that MSY
remained intact in both the cell lines.
In an earlier report, Y chromosome was excluded from
the CGH analysis because of the presence of a large het-
erochromatic region [39]. In this study, we particularly
focused on the heterochromatic region DYZ1 and
assessed not only its copy number variation but also
indels all along the length of the array. We detected 742
copies in DU145 and that of 1945 in LNCaP cells. Sig-
nificant difference in the copy number of DYZ1 between
DU145 and LNCaP could be due to the unequal number
of Y chromosome(s) per cell. It may be noted that
DU145 carries single Y chromosome per cell coupled
with a major translocation of part of 20th chromosome
to the Y chromosome, whereas LNCaP carries 2 Y chro-
mosomes per cell [3]. In an earlier study on the biopsied
samples of PC, we detected 550 copies of the DYZ1 [26]
which is in accordance with our present study.
Though MSY was intact in DU145 and LNCaP cells
but DYZ1 was clearly affected showing insertion, dele-
tion, frequent point mutations and copy number varia-
tions. These mutational events, not only shifts the frame
of abundant “TTCCA” repeats but also generate its de-
rivatives leading to the shrinkage or expansion of the
same. The insertion and deletion of 16 bp kept the frame
unchanged and maintained the original length of array
of 3564 bp in DU145. Due to insertion of 15 bp and de-
letion of 114 bp, the LNCaP cells showed net loss of
99 bp in the array of 3564 bp (Additional file 3). A normal
array of 3564 bp harbours approximately 80 different re-
striction enzyme recognition sites [25]. We detected more
loss of restriction sites in both the cell lines than that of
their gains. Startlingly, a single Eco57I site was gained in
both the cell types though its biological significance
remained unclear. These results clearly suggest that DYZ1
is indeed affected during the process of cells becoming
cancerous. Despite these changes, Y chromosome survived
in about 58% of DU145 cells (Figure 7). Most likely, such
DU145 cells have managed to retain the critical number
Figure 6 Copy number estimation of DYZ1 in DU145 and LNCaP. (A) represents the amplification plot, (B), the corresponding dissociation
curve (C), the standard plot and (D) shows the number of DYZ1 copies in DU145 and LNCaP.
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for the sustenance of the Y chromosome.
The African-American men have been found to show
highest and Japanese, the lowest incidences of PC in the
world [40-42]. This suggests that males from different eth-
nicity and geographical regions may be different with re-
spect to their susceptibility to develop prostate cancer. It
may be noted that status of DYZ1 was not assessed in the
males from either of these populations. Based on our
study, we presume that besides susceptibility to PC, males
from different ethnic and geographical regions may show
sequence and copy number variations in the DYZ1 arrays.
However, this warrants a detailed analysis of sufficient
number of PC males before a conclusion can be drawn.
When, once this issue is fully resolved, DYZ1 may be
added amongst the list of possible bio-marker for DNA
based diagnosis using PC biopsied samples.
Conclusions
Our study demonstrates that, MSY region and SRY gene
both remain intact in DU145 and LNCaP PC cell lines.
Since, DYZ1 region is maximally affected both in termsof sequence and array’s copy number; this may be
exploited as possible bio-marker for DNA based diagno-
sis of PC together with other marker systems.
Methods
Cell culture and DNA isolation
DU145 and LNCaP cell lines were available with National
Institute of Immunology, New Delhi and Jawaharlal Nehru
University, New Delhi, respectively in connection with
other projects. Institute and University procured this cell
lines from ATCC (American Type Culture Collection,
Manassas, USA). DU145 cells were cultured in T75 flasks
containing 10% DMEM (Dulbecco’s Modified Eagle
Medium, Life Technologies, Gibco, USA). LNCaP cells
were cultured in T75 flask containing 10% RPMI 1640 (Life
Technologies, Gibco, USA). Cultures were supplemented
with 1% antibiotic and antimycotic solution.
DNA from cultured cells was isolated using DNeasy
Blood and Tissue kit (Qiagen, Germany). Quality of
isolated DNA was checked by electrophoresis using
1% agarose gel and concentration was measured
spectrophotometrically.
Table 6 Restriction mapping of 3.56 Kb DYZ1 sequence from DU145, LNCaP and the reference sequence AC068123.5







Overhung Frequency of cut sites
AC068123.5 DU145 LNCaP
1 BsaBI GATNNNNATC 6 blunt 1 0 0
2 Cac8I GCNNGC 4 blunt 1 1 1
3 NlaIV GGNNCC 4 blunt 1 0 0
4 BamHI GGATCC 6 5’ 1 0 0
5 BseYI CCCAGC 6 5’ 1 1 1
6 Bsp1407I TGTACA 6 5’ 1 1 1
7 BspHI TCATGA 6 5’ 1 1 1
8 ClaI ATCGAT 6 5’ 1 1 1
9 DdeI CTNAG 4 5’ 1 1 1
10 EcoRI GAATTC 6 5’ 1 1 1
11 EcoRII CCWGG 5 5’ 1 0 0
12 MaeII ACGT 4 5’ 1 1 0
13 MaeIII GTNAC 4 5’ 1 1 0
14 VspI ATTAAT 6 5’ 1 1 1
15 XhoII RGATCY 6 5’ 1 0 0
16 BseMII CTCAG 5 3’ 1 1 1
17 BsgI GTGCAG 6 3’ 1 1 1
18 BtsI GCAGTG 6 3’ 1 1 1
19 Eco57I CTGAAG 6 3’ 0 1 1
20 Eco57MI CTGRAG 6 3’ 1 2 2
21 GsuI CTGGAG 6 3’ 1 1 1
22 Hpy188I TCNGA 4 3’ 1 1 1
23 MnlI CCTC 4 3’ 1 1 1
24 PflMI CCANNNNNTGG 6 3’ 1 1 1
25 SduI GDGCHC 6 3’ 1 1 1
26 ScrFI CCNGG 4 5’ 2 1 1
27 ArsI GACNNNNNNTTYG 7 3’ 2 2 2
28 BdaI TGANNNNNNTCA 6 3’ 2 2 2
29 CspCI CAANNNNNGTGG 7 3’ 2 0 0
30 TspRI CASTG 5 3’ 2 2 2
31 DpnI GATC 4 blunt 3 2 2
32 ApoI RAATTY 6 5’ 3 3 3
33 AsuII TTCGAA 6 5’ 3 3 3
34 Eco31I GGTCTC 6 5’ 3 2 2
35 MaeI CTAG 4 5’ 3 3 4
36 MboI GATC 4 5’ 3 2 2
37 SfaNI GCATC 5 5’ 3 4 4
38 TatI WGTACW 6 5’ 3 3 3
39 SetI ASST 4 3’ 3 3 1
40 CviJI RGCY 4 blunt 4 4 4
41 MslI CAYNNNNRTG 6 blunt 4 4 4
42 FokI GGATG 5 5’ 4 2 2
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Table 6 Restriction mapping of 3.56 Kb DYZ1 sequence from DU145, LNCaP and the reference sequence AC068123.5
by virtual digest using Restriction Mapper Version 3 software (Continued)
43 AlfI GCANNNNNNTGC 6 3’ 4 4 4
44 RsaI GTAC 4 blunt 5 5 4
45 BccI CCATC 5 5’ 5 3 4
46 BsmAI GTCTC 5 5’ 5 5 4
47 MseI TTAA 4 5’ 5 6 6
48 BstXI CCANNNNNNTGG 6 3’ 5 5 4
49 MboII GAAGA 5 3’ 5 3 3
50 XmnI GAANNNNTTC 6 blunt 6 6 6
51 TstI CACNNNNNNTCC 6 3’ 6 4 4
52 NlaIII CATG 4 3’ 7 7 7
53 BcgI CGANNNNNNTGC 6 3’ 16 14 14
54 BsrDI GCAATG 6 3’ 16 14 14
55 BsrI ACTGG 5 3’ 17 19 18
56 TspGWI ACGGA 5 3’ 20 23 17
57 AgsI TTSAA 5 3’ 22 20 23
58 BsmI GAATGC 6 3’ 22 23 21
59 FaiI YATR 4 blunt 23 25 23
60 PleI GAGTC 5 5’ 23 21 21
61 TspDTI ATGAA 5 3’ 25 24 24
62 TspEI AATT 4 5’ 35 35 35
63 TfiI GAWTC 5 5’ 52 51 51
64 TaqI TCGA 4 5’ 66 62 62
65 HinfI GANTC 4 5’ 75 72 72
The loss or gains of the restriction sites with respect to the reference sequence are highlighted in bold.
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MSY region was analysed for micro-deletions using STS
end point PCR reactions. A total of 51 STSs were selected
from the MSY breakpoint mapper for screening this re-
gion. The end point PCR reactions were performed in
20 μl reaction volumes containing 5X Green Go Taq reac-
tion buffer (Promega, Madison, USA), 200 μM dNTPs
(Biotools, Spain), 1 IU Go Taq polymerase (Promega,
Madison, USA) and 100 ng of genomic DNA. STS PCR
primers were procured from Sigma-Aldrich, USA. STS
screening was performed following the PCR conditions
available in MSY Breakpoint Mapper database [17]. β-actin
(Forward primer- 5’ AGATGACCCAGATCATGTTTGA
GA 3’ and Reverse primer- 5’ CTAAGTCATAGTCCGCC
TAGAAGC) and sY14 (Additional file 4) primers were
used as control for assessing the quality of genomic
DNA. Genomic DNA from normal males were used as
positive controls. Female genomic DNA and a reaction
without template were used as negative controls. The
amplified products were resolved on 1.5% agarose gel,
stained with ethidium bromide and visualized under
UV illumination.Single Nucleotide Variants (SNV) analysis
The AZFc region of MSY was analyzed for 7 SNVs in
the DAZ region and one SNV for GOLY1, BPY2 and
TTTY4 by PCR-restriction fragment length polymorph-
ism. The details of primer sequences, accession num-
bers, product sizes and restriction enzymes used for
SNV analysis are given in the Table 2. SNV PCR reac-
tions were performed in 40 μl following standard PCR
conditions. The amplified PCR product was precipitated
by addition of 4 μl of 3 M sodium acetate and 120 μl of
absolute ethanol and incubated at -70°C for 4 hours.
DNA was pelleted down at 13,000 rpm for 20 minutes at
4°C, washed in 70% ethanol, dried and dissolved in 10 μl
water. The purified PCR products were further subjected
to restriction digestion using appropriate restriction en-
zymes and buffer. The digested fragments were resolved
on 2.5% agarose gel, stained with ethidium bromide and
visualized under UV illumination.
Cloning and sequencing of SRY and DYZ1 array
Pfu DNA polymerase (Biotools, Spain) amplified amplicons
were resolved on 1.5% agarose gel, sliced and eluted using
Figure 7 Localization of DYZ1 in DU145 cells by FISH. DAPI (4’, 6-diamidino-2-phenylindole) stained metaphases and interphase nuclei are
shown having green signal of DYZ1. Nuclei and metaphases lacking DYZ1 are indicated by red arrow. Note the variation in the DYZ1 signal
intensities across nuclei reflecting copy number variation.
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Eluted DNA was cloned in pGEM®-T easy vector
(Promega, Madison, USA). 4 recombinant clones for each
fragment were sequenced on Applied Biosystems 3130xl
Genetic Analyzer using ABI PRISM® BigDye® terminator
v3.1 cycle sequencing kit (Life Technologies, California,
USA). For cycle sequencing, PCR reactions were set as
96°C for 1 minute, followed by 25 cycles each consisting of
96°C for 10 seconds, 50°C for 5 seconds, and 60°C
for 4 minutes. After PCR, extension products were
purified using ethanol–sodium acetate precipitation
method followed by washing in 70% ethanol. Hi-DiTM
Formamide (Life Technologies, California, USA) was
added, samples were heat denatured, chilled on ice and
loaded on ABI 3130xl genetic analyzer. Sequencing
was performed using Run 3130xl Data Collection soft-
ware v3.0, sequences were retrieved using Sequencing
Analysis 5.3.1 and sequence analysis was done using
Gene runner software.
Analysis of DYZ1 array
The intactness of DYZ1 array was assessed using end
point PCR. The details of primers, their combinations
and PCR conditions are listed in the Table 4. Copy num-
ber of DYZ1 was calculated based on absolute quantifi-
cation method using qPCR. DNA was used as template
and SYBR green (Life Technologies, California, USA)was used as detection dye. The qPCR reactions were
performed on Sequence Detection System 7500 (Life
Technologies, California, USA). 10 fold dilutions of re-
combinant plasmid containing ~3.56 Kb HaeIII fragment
of DYZ1 array were used to generate standard curve
starting with 2 X 108 copies. All the reactions were car-
ried out in triplicates using three different concentra-
tions of the template DNA from DU145 and LNCaP
cells. The standard curve had a slope of −3.32 and R2
value of >0.99. Copies of the DYZ1 array were calculated
by extrapolation of the standard curve obtained with
known copies of the recombinant plasmid.
Florescence in-situ hybridization (FISH)
DU145 cells cultured in 10% DMEM were used for
metaphase chromosome preparation. These cells were
grown for 70 hours in 5% CO2 environment at 37°C and
then treated with colcemid (3 μg/ml). Treated cells were
again incubated for 2 hours in 5% CO2 environment at
37°C. After 72 hours, cells were centrifuged at 1800 rpm
for 10 minutes at room temperature (RT). Harvested
cells were resuspended in 0.075 M KCl and incubated at
RT for 20 minutes in 5% CO2 environment at 37°C.
Then added 1 drop of fixative solution (3:1, methanol: gla-
cial acetic acid) and centrifuged at 1800 rpm for 10 mi-
nutes at RT. Discarded the supernatant, resuspended the
cell pellet in 10 ml fresh fixative solution and incubated
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for 10 minutes at RT. Repeated the washing step 2 times.
Finally, cells were resuspended in fresh 1 ml fixative and
stored at -20°C.
For metaphase chromosome preparation, 20 μl of nu-
clei suspension in fixative was spread on the glass slides.
Before proceeding further, slides were kept for 1 week at
37°C for ageing. Slides were then incubated in 70% gla-
cial acetic acid for 2 minutes followed by dehydration in
70%, 90% and 100% ethanol for 2 minutes each at RT.
Air dried the glass slides and incubated in a solution
containing 0.1 mg/ml and 0.01 N HCl for 20 minutes.
Fixed the metaphase preparation in 4% paraformalde-
hyde (prepared in 1X PBS, pH 7.4) for 5 minutes at RT.
Slides were then washed in 1.0 M Tris–HCl (pH 7.4)
followed by 2 washes in 1X phosphate buffer saline
(PBS) for 5 minutes each at RT. Further, incubated in
0.5% Triton-X-100 (prepared in 1X PBS) for 10 minutes
followed by 3 washes in 1X PBS for 5 minutes each.
Slides were then incubated in 0.1 N HCl for 10 minutes
followed by 3 washes in 1X PBS for 5 minutes each and
stored in 2X SSC (pH 7.4) overnight at 4°C until used for
hybridization. FISH was conducted with a labelled clone
containing 3.56 kb sequence of DYZ1. Labelling was done
with biotin-dUTP using a Nick translation kit from Vysis
(Illinois, USA). Hybridization, washing, counterstaining
and mounting of the slides were conducted following
standard protocols [43]. The slides were screened under
the Olympus fluorescence microscope (BX 51) fitted with
vertical fluorescence illuminator U-LH100HG UV, excita-
tion and barrier filters and images were captured with a
charge-coupled device (CCD) camera. Captured images
were analyzed using CytoVision software version 3.93
from Applied Imaging Systems.
Additional files
Additional file 1: Multiple Sequence Alignment (MSA) of the SRY
gene cloned and sequenced from DU145 and LNCaP with that of
normal sequence (Accession number- NM_003140) in the database.
Coding region starts at 89thbp and ends at 703 bp. MSA showed no
sequence alteration within the SRY gene.
Additional file 2: Complete 3.56 Kb DYZ1 sequences of the
reference sequence AC068123.5 (A), DU145 (B), and LNCaP (C), all
showing in frame arrangement of the pentanucleotide motifs.
Additional file 3: Multiple Sequence Alignment of 3.56 Kb
sequence of DYZ1 array from DU145 and LNCaP with sequence
from the NCBI database (Accession no. AC068123.5, Gene ID-
100499443). Perfectly aligned sequences are indicated by star and
deletions, by hyphens. Mismatched base pairs, deletions or
insertions are highlighted in green colour.
Additional file 4: Details of STS primers used for screening MSY
region.
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